Table 5.
Univariate Cox regression analysis of factors associated with overall survival
| Hazard ratio (95% CI) | P-value | |
|---|---|---|
| Age | 1.02 (1.01–1.03) | <0.001 |
| MELD score | 1.02 (1.01–1.02) | <0.001 |
| BMI | 1.00 (0.99–1.01) | 0.478 |
| Gender | 0.909 | |
| Female | 1.00 | |
| Male | 1.01 (0.88–1.15) | |
| Race | <0.001 | |
| White | 1.00 | |
| African-American | 1.24 (1.04–1.48) | 0.018 |
| Asian | 0.72 (0.58–0.89) | 0.003 |
| Hispanic | 0.93 (0.80–1.09) | 0.368 |
| Other | 0.64 (0.37–1.10) | 0.105 |
| Cirrhosis | 0.844 | |
| No | 1.00 | |
| Yes | 0.99 (0.87–1.12) | |
| Diabetes | 0.010 | |
| No | 1.00 | |
| Yes | 1.17 (1.04–1.31) | |
| Lamivudine therapy | 0.803 | |
| No | 1.00 | |
| Yes | 0.95 (0.66–1.37) | |
| Hepatitis B immunoglobulin | 0.008 | |
| No | 1.00 | |
| Yes | 0.69 (0.53–0.91) | |
| Viral status | <0.001 | |
| HBV−/HCV− | 1.00 | |
| HBV+/HCV− | 0.68 (0.52–0.88) | 0.004 |
| HBV−/HCV+ | 1.14 (1.01–1.29) | 0.034 |
| HBV+/HCV+ | 1.05 (0.71–1.57) | 0.799 |
95% CI, 95% confidence interval; MELD, Model for End-stage Liver Disease; BMI, body mass index; HBV, hepatitis B virus; HCV, hepatitis C virus.